Background: Cachexia in chronic heart failure carries a poor prognosis, but little is known about the influence of body mass on the prognosis of noncachectic heart failure patients. Methods: We studied 589 consecutive chronic heart failure patients followed for at least a year, in whom there were accurate baseline data for body mass. 
Cardiac cachexia has been recognized since ancient times, 1 and has recently received much research interest.
The prognosis of patients with chronic heart failure and cachexia is much worse than for patients without cachexia but with a similar degree of left ventricular dysfunction. 2 The development of cachexia can be seen as a marker of more severe disease, perhaps by indicating a more marked neurohormonal response to the heart failure state. 3 In the wider population, obesity has become a major health problem associated with poor health and increased mortality, [4] [5] [6] but in chronic heart failure, cachexia is a poor adverse prognostic feature. 2 Cachexia is defined as a state of incremental weight loss, but nothing is known of the effect of body mass and particularly of obesity on survival in the general population of patients with heart failure without cachexia. A previous study has suggested that increasing body mass index (BMI) is associated with improved survival, 7 but did not exclude patients with cachexia from that analysis. We hypothesized that, because chronic heart failure appears to be an inherently catabolic state, 8, 9 higher body mass might prove protective even in the absence of cachexia.
The present article reports the survival of a group of 525 patients with chronic heart failure and no record of weight loss at the time of entry into the study. The survival of 64 patients with cachexia is shown.
Methods
We evaluated 589 unselected consecutive patients with chronic heart failure presenting at the Heart Failure Clinic of the Royal Brompton Hospital between March 1991 and January 2000 (Table 1 ). This is a mixed secondary and tertiary referral center for cardiology. The diagnosis of heart failure was made on the basis of symptoms of shortness of breath and symptomatic exercise intolerance with signs of pulmonary congestion or peripheral edema in the presence of objective evidence of left ventricular systolic dysfunction by echocardiography or radionuclide ventriculography.
After the diagnosis was made, the medical regimen of all the enrolled patients was optimized. Medications included digoxin, angiotensin-converting enzyme inhibitors, diuretics, nitrates, ␤-blockers, statins, and aspirin or warfarin in varying combinations. Details are given in Table 2 . Cachectic patients were more likely to be taking digoxin, but there were no other significant differences between the cachectic and noncachectic patients.
At presentation, all patients were examined clinically. Weight and height were measured and the BMI (BMI ϭ weight/height 2 ) was calculated. The medical notes were reviewed and a history of weight change was carefully taken to document weight loss. Cardiac cachexia was defined as documented nonedematous and nonintentional weight loss of >7.5% of the previous nonedematous weight over at least 6 months (n ϭ 64). No patient was suspected either clinically or after examination or investigation to have any other primary cachectic state (infection, malignant disorder, thyroid disease, severe liver disease, or acquired immunodeficiency syndrome). The noncachectic heart failure patients had no history of significant nonedematous weight loss in the 2 years before the study and were documented not to meet the definition of cachexia. We used the European Society of Cardiology Guidelines 10 for heart failure treatment to define patients as overweight and obese.
All subjects underwent echocardiography to assess cardiac function. Resting left right ventricular ejection fraction (LVEF) and right ventricular ejection fraction were determined in 426 (72%) and 190 (32%) patients by radionuclide ventriculography.
Symptom-limited cardiopulmonary exercise testing with respiratory gas exchange was performed in 502 patients (85%) using the modified Bruce protocol, in which there was a stage zero of 1 mph at 5% gradient. NYHA, New York Heart Association; IHD, ischemic heart disease; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic dimension from two-dimensional echocardiography; BMI, body mass index; VO 2 , oxygen consumption; VE/VCO 2 slope, the relation between ventilation and carbon dioxide production.
Measurements from two-dimensional scans were not available in all patients.
Oxygen consumption, minute ventilation, and carbon dioxide production were measured online every 10 seconds by a standard inert gas dilution technique (Amis 2000, Odense, Denmark). 12 Patients were encouraged to exercise to exhaustion. The peak oxygen consumption (peak VO 2 ) was defined as the highest VO 2 observed during exercise. The ventilatory response to exercise was measured as the slope relating ventilation to carbon dioxide production in 500 patients. All but 52 patients (10%) achieved a respiratory exchange ratio >1.00, indicating the achievement of anaerobic exercise conditions (mean 1.14 Ϯ 0.14).
Follow-up
All patients were followed up by the Royal Brompton Hospital Heart Failure Clinic. The primary endpoint of the study was all-cause mortality. Ascertainment was complete; all patients were under active follow-up or known to have died. The general practitioner was contacted when a patient had been "lost" to follow-up and the patient's status confirmed. Data were censored at January 1, 2001, to ensure complete follow-up of at least 12 months in all cases. In many cases, death occurred outside of the hospital, and post mortems were not carried out. It was not possible to establish the cause of death, and therefore this study focuses on all-cause mortality.
Statistical Analysis
Statistical analysis was performed using a standard statistical program package (StatView 4.5, SAS Institute Inc., Cary, NC). Numeric values are presented as mean Ϯ standard deviation. Noncachectic HF patients were categorized in quintiles according to their BMI. Because we were unable to correct peak VO 2 for lean body mass, we used VO 2 per kg, and also per kg normalized for BMI. The unpaired Student t-test and analysis of variance (ANOVA) were used where appropriate. Where ANOVA demonstrated significant differences, post hoc analysis was made using Fisher's projected least significant difference test. A P value < .05 was considered statistically significant. The Cox proportional-hazards model with the likelihood ratio test was used to assess the impact of clinical history and test results on time to death in univariate and multivariate analyses. Death was coded as a binary event, with time to follow-up coded in months. To adjust for the large number of variables tested for their relationship to survival, in survival analyses P < .01 was considered statistically significant. Cumulative survival plots for patient groups were calculated using the Kaplan-Meier method.
Results
Clinical data for the 525 patients with no history of weight loss are shown in Table 1 . For comparison, data on the group of 64 cachectic heart failure patients are also shown. The cachectic patients were, on average, 4 years older and tended to have worse heart failure as evidenced by worse exercise capacity, lower blood pressure, and a lower LVEF.
In the noncachectic group, 84.0% of patients were receiving an angiotensin-converting enzyme inhibitor or angiotensin II receptor antagonist. The proportion was 87.1% in the cachectic group; 9% and 11% were not receiving diuretic therapy in the two groups, respectively. Other drug therapy is shown in Table 2 . Consistent with the time of recruitment into the study, there was a low level of ␤-adrenoceptor antagonist use.
In the noncachectic patients, peak VO 2 was strongly related to body mass (r ϭ .5; P < .0001). In further analysis, we thus used peak VO 2 corrected for body weight.
Mean follow-up in the survivors was 53.0 Ϯ 25.2 months. At 1 January 2001, 167 of the noncachectic and Fig. 1 . Survival at 12 and 36 months (with 95% CI) was 87% (84-90) and 72% (68-76) in the noncachectic patients and 67% (55-79) and 37% in the cachectic group (P < .0001 for both comparisons).
To assess the effect of body mass on survival in patients without cachexia, we divided the patients into quintiles of body mass index. Comparative data for the 5 groups are shown in Table 3 . Blood pressure (both systolic and diastolic) was somewhat higher in the heavier groups. The best survival was seen in the moderately obese 4th quintile. The comparative risk ratios and 1-and 3-year survival rates are shown in Table 4 . Of all the comparisons between quintiles, only those between Q4 and the others demonstrated statistical significance (shown in Table 4 ). There was no significant difference between Q4 and Q5. The importance of BMI persisted after correction for age, underlying diagnosis and New York Heart Association class using the Cox proportional hazards model. The effect of BMI quintile on survival was not materially different when the patients with preserved systolic function were excluded from analysis.
The survival overall for patients in the lowest quintile was greater than for cachectic patients (hazard ratio 0.55; 95% CI 0.36-0.84; P ϭ .005), but very similar over the first 2 years (2-year survival: 53% (46%-61%) quintile 5; 47% (35%-59%) cachectics; log rank 2 1.6: P ϭ .21). Table 5 shows the survival for patients based on whether the patients might have been recommended to lose weight based on the European Society guidelines. 10 Those patients deemed overweight by conventional criteria fared less well, whether the cachectic patients were included in the analysis or not.
Univariate predictors of survival are shown in Table 6 . Age, diagnosis, peak VO 2 , LVEF, and BMI were entered into a multivariate analysis for 1-year follow-up (the last time point for which there was complete follow up). Peak There was no significant difference in the duration of heart failure between the 5 quintiles and between the quintiles and the patients with cachexia, but a relation between duration of heart failure (per month) and survival ( 
Discussion
Obesity is an epidemic of Westernized societies 13 and is strongly related to the development of cardiovascular disease. [14] [15] [16] In apparently healthy subjects, the risk or coronary disease starts rising above a BMI of approximately 23.5 to 24.9 in men 17 and approximately 22 in women. 18, 19 By contrast, weight loss lowers the risk factors associated with coronary disease in the obese, 20 Other than the differences between the groups in body mass index and % ideal weight, there was no significant difference between the groups in any of the variables reported apart from blood pressure. Diagnosis is presented as proportion of patients with an underlying diagnosis of ischemic heart disease.
LVEF > 45% is the proportion of each group with preserved LV systolic function. The P value for these row is from a 2 test. Other P values are for analysis of variance using all groups. Abbreviations as in Table 1 .
although there is some evidence to suggest that both voluntary and nonvoluntary weight loss are associated with increases in all-cause mortality in otherwise apparently healthy people. 21, 22 Cachexia is associated with a poor outcome in a variety of disease states-for example, in chronic renal failure, 23 after cardiac surgery, 24, 25 in patients with dementia 26 and chronic lung disease, 27 as well as malignant disease (for review see references 28 and 29) . We have previously demonstrated that cachexia is associated with a poor prognosis in patients with chronic heart failure 2 in whom cachexia was defined as a process of weight loss.
The present study confirms these results in a larger group of patients. We were mainly concerned about addressing the issue of whether body mass affected survival in the absence of active weight loss. Previous investigators have suggested that there is a relation between increasing BMI and improved survival, 7 but did not exclude patients with cachexia. The patients in this study were documented not to have lost weight before the study. We have found that the best survival was seen in moderately obese subjects, with a relative risk of 2.3 in the quintile of patients with an "ideal" BMI of 22 (in this study, these patients are in the lightest quartile with a BMI of 22.2 Ϯ 1.5). 16 Increasing BMI was a predictor of 1-year survival independent of exercise capacity and left ventricular function.
Chronic heart failure is a catabolic state. 3 The origins of catabolism remain uncertain, but are related neurohormonal systems activated as part of the response to the heart failure syndrome. Patients with moderate obesity may represent a group of patients with a higher metabolic reserve, who are better (and longer) able to tolerate the metabolic stress of heart failure than those with more "ideal" body weights. The heavier patients had higher blood pressure than the controls. This may represent an effect of obesity per se, rather than reflecting better cardiac function. Other variables suggest that the severity of heart failure was the same in all groups. The role of nutritional support for heart failure patients needs to be investigated further. 30 The survival rate of the lowest quintile patients was similar to that of cachectic patients over the first 2 years of follow up (although not overall). This raises the possibility of misclassification of patients as noncachectic, although we were careful only to include as patients with documented absence of weight loss as noncachectic. We have not been able to correct peak exercise capacity for lean body mass because few of these patients have had dual energy x-ray absorptiometry (DEXA) scanning, and it we cannot say whether one body compartment or another (fat or lean body mass) is most strongly related to survival. We tried to get an impression of the effect of correcting peak VO 2 for lean body mass by using peak VO 2 /kg normalized for BMI. We found that this approach increased the statistical significance attributable to the effect of increasing BMI on survival. The coefficient describes the change in relative risk per unitary increase in a continuous variable. For diagnosis, the relative risk for dilated vs. ischemic etiology is shown. For NYHA, the risks relative to class IV were: I, 0.116; II, 0.235; III, 0.473.
Abbreviations as in Table 1 .
A further possibility is that there is a U-shaped relation between BMI and survival in heart failure, with worse survival for the heaviest patients. There was no difference between the 2 heaviest quartiles in our analysis, but there were too few very heavy patients to answer this question with these data. The lightest quartile might have been underweight through excessive diuresis, which itself might carry an adverse prognosis. However, the diuretic dose was not significantly different between the 5 groups, and, at most, this factor could only have contributed 1-2 kg.
In summary, this study suggests that from the standpoint of survival, the "ideal" body weight is higher for heart failure patients than in the general population; this seems to be true regardless of whether the patient has an ischemic etiology.
